Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XZP-3621 in ALK-positive advanced NSCLC (phase II, single-arm)
CTR20221791Phase 2Completed
- Sponsor
- Xuanzhu Biopharmaceutical
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dirozalkib in ALK-positive non-small cell lung cancer, sponsored by Xuanzhu Biopharmaceutical. Started Jul 2022; status: completed.
02
Drugs
dirozalkib
03
Conditions
ALK-positive non-small cell lung cancer
Beyond the preview
Go deeper on CTR20221791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221791.